Advertisement
Australia markets close in 3 hours 41 minutes

  • ALL ORDS

    7,758.20
    -140.70 (-1.78%)
     

  • ASX 200

    7,505.60
    -136.50 (-1.79%)
     

  • AUD/USD

    0.6371
    -0.0054 (-0.85%)
     

  • OIL

    85.78
    +3.05 (+3.69%)
     

  • GOLD

    2,425.30
    +27.30 (+1.14%)
     

  • Bitcoin AUD

    94,145.52
    -2,440.94 (-2.53%)
     

  • CMC Crypto 200

    1,255.47
    +369.94 (+39.29%)
     

  • AUD/EUR

    0.5997
    -0.0034 (-0.56%)
     

  • AUD/NZD

    1.0875
    0.0000 (0.00%)
     

  • NZX 50

    11,755.18
    -80.86 (-0.68%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,187.65
    -198.22 (-1.21%)
     

  • NIKKEI 225

    36,799.75
    -1,279.95 (-3.36%)
     

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

Xenon Pharmaceuticals Inc.
·1-min read
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 1, 2023.

Conference Call/Webcast Information:

Date:

Wednesday, March 1, 2023

 

 

Time:

4:30 pm Eastern Time (1:30 pm Pacific Time)

 

 

Dial-In:

(800) 715-9871 or (646) 307-1963 for international callers

 

 

Conference ID:

5740430

 

 

A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

ADVERTISEMENT

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: (604) 484-3353
Email: investors@xenon-pharma.com